[Accesswire] – LONDON, UK / ACCESSWIRE / July 22, 2016 / Active Wall St. announces its post-earnings coverage on Biogen Inc. (NASDAQ: BIIB ). The company announced its Q2 FY16 financial results before the opening bell … Read more on this. , with a current market cap of $ecting to http://finance.ya, ended session yesterday at $. Looking at today’s market, BIIB one day range is $ and has traded between $ over the past year. BIIB shares are currently priced at x this year’s forecasted earnings, which makes them relatively inexpensive compared to the industry’s x forward p/e ratio. In a review of the consensus earnings estimate this quarter, 0 sell-side analysts are looking at $ per share, which would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. Investors should also note that the full-year EPS estimate of $ is a $0.00 setback when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $0.00 . If reported, that would be a 0.00% decrease over the year-ago quarter. More recently, d BIIB from to (/fin). Previously, d BIIB from to . When considering if perhaps the stock is under or overvalued, the average price target is $, which is 0.00% below where the stock opened this morning. See more in (NASDAQ:BIIB) Similar Articles: Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016 Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Appoints Michael Ehlers Executive Vice President, Research and Development